N.J., March 3, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the acquisition and launch 1 of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials.

DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

Banking shares stole the show among the sectoral indices, with PSU banks leading the charge, as the Nifty PSU Bank index ...

Bengaluru: Biocon has announced that Biocon Pharma Limited, a wholly owned subsidiary of the Company, has received approval ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

This simple method has the following advantages: (1) the vials themselves are not contaminated; (2) the volume of scintillation fluid is only 2 ml, thus reducing costs; (3) the specimen tubes are ...

Sensex, Nifty updates on 24 March 2025. The benchmark BSE Sensex jumped 1.4% to 77,984.38, while the NSE Nifty gained 1.32% ...

In downstream processing of biopharmaceutical products, protein aggregation presents one of the main risks in terms of ...

Dr. Reddy and Alvotech announce the FDA acceptance of the BLA for their proposed biosimilar candidate of Amgen's Prolia and Xgeva for review.